Background: The obesity paradox refers to the finding in observational studies that patients with obesity have a better prognosis after stroke than normal weight patients.
Introduction
Over 65% of the U.S. population is overweight or obese. 1 Excess weight, as most commonly measured by body mass index (BMI) or waist circumference (WC), is associated with increased risk for stroke and myocardial infarction (MI). 2 The adverse effect of increased weight on cardiovascular outcomes is thought to result primarily from the consequences of metabolic impairment, such as hypertension, dyslipidemia, vascular inflammation, insulin resistance, hyperglycemia, and abnormal vascular reactivity. 3 Despite the strong association of overweight and obesity with first stroke or MI, overweight and obese patients with existing cardiovascular disease have been found to be at lower risk for recurrent events and mortality compared with normal weight patients. [4] [5] [6] [7] Several explanations have been offered for this ''obesity paradox,'' 8 but most evidence supports error in classifying obesity and two types of bias in observational research: index event and reverse causation. Classification error may occur because the most common measure of adiposity, BMI, is an indirect measure of obesity. More direct measures, particularly percentage of body fat, have been associated with increased mortality in population-based samples. 9, 10 Index event bias can occur when research populations are selected for the occurrence of a baseline event (e.g., first stroke) that is associated with a prior exposure (e.g., obesity). 11, 12 Subsequent risk in patients with this exposure may be lower than risk in persons without the exposure if the factors that caused the baseline event (e.g., atrial fibrillation) in the unexposed are more virulent causes of future adverse outcomes. Reverse causation bias 13 occurs when patients with an underlying disease (e.g., cancer) associated with poor prognosis lose weight before the acute event, thus, linking lower weight with subsequent increased mortality.
Hypothesis
Clarification of the relationship between increased weight and prognosis after stroke may require experimental research, such as randomized clinical trials, to determine if intentional weight reduction leads to fewer adverse outcomes. Pending such studies, however, it may be possible to identify overweight or obese patients who are at particularly high or low risk for recurrent vascular disease. In this research, therefore, we test the hypothesis that the presence of more severe metabolic impairment, as defined by the metabolic syndrome, identifies patients at higher risk of recurrent vascular disease.
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Methods
Study population
The study cohort consisted of participants in the Insulin Resistance Intervention after Stroke (IRIS) trial, 18 a randomized, placebo-controlled clinical trial that tested the effectiveness of pioglitazone (an insulin sensitizer) for the prevention of stroke and MI among insulin-resistant, non-diabetic patients with a recent ischemic stroke or TIA. Insulin resistance was defined by a value over 3.0 on the homeostasis model assessment of insulin resistance (HOMA-IR). Additional eligibility criteria included age 40 years or older and ischemic stroke or TIA within the previous 180 days. The study enrolled 3876 participants between February 2005 and January 2013 from 179 sites in seven countries (Australia, Canada, Germany, Israel, Italy, United Kingdom, and the United States). Participants were followed for up to 5 years (median 4.8 years). 19 All participating institutional review boards approved the study, and all patients provided written informed consent. Members of independent committees adjudicated stroke, MI, and death events blinded to treatment assignment.
Definitions of obesity and metabolic syndrome
Body morphology at the time of entry into the IRIS trial was classified by BMI, WC, and waistto-hip ratio (WHR). BMI was categorized using conventional definitions of normal weight (18.5 to < 25 kg/m 2 ), overweight (25 to < 30 kg/m 2 ), and obese (!30 kg/m 2 ). 20 IRIS patients who were underweight at entry (BMI < 18.5 mg/kg 2 ) were excluded from this study cohort. Based on the World Health Organization criteria, 21 abdominal obesity was defined as WC ! 102 cm for men and ! 88 cm for women, and elevated WHR was defined as !0.9 for men and !0.85 for women.
Metabolic syndrome was defined using the harmonized criteria. 22 Specifically, a participant was classified as having metabolic syndrome if three of the following were present at baseline: (1) WC ! 102 cm in men or !88 cm in women; (2) high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL in men or <50 mg/dL in women or taking drug treatment for reduced HDL-C (i.e., fibrates or nicotinic acid); (3) elevated blood pressure (systolic ! 130 mm Hg or diastolic !85 mm Hg) or self-reported history of hypertension and taking antihypertensive medication; (4) triglycerides ! 150 mg/dL or taking drug treatment for elevated triglycerides (i.e., fibrates, nicotinic acid, or high-dose omega-3 fatty acids); and (5) fasting glucose ! 100 mg/dL. Patients on treatment for diabetes or with glucose !126 mg/dL were excluded from IRIS.
Values for fasting glucose, insulin, lipids, and C-reactive protein were measured using standardized assays. Demographic and clinical characteristics were classified by self-report and included age, sex, race, years of education, current cigarette smoking, coronary artery disease (CAD), prior stroke (before index stroke or TIA), and peripheral vascular disease (PVD). The site principal investigator determined the presence or history of atrial fibrillation.
Statistical analysis
We first examined the association between three adiposity measures and risk for outcomes (stroke or MI, all-cause mortality, stroke alone, and MI alone). Hazard ratios (HRs) and 95% confidence intervals for each adiposity category were estimated using Coxproportional hazard models with the normal category (BMI: 18.5-24.9 kg/m 2 ; no abdominal obesity; nonelevated WHR) as the reference group. Adjusted models were estimated with inclusion of 10 prespecified baseline features: age, sex, race, treatment
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Results
Baseline features by adiposity strata
Of 3876 patients enrolled in IRIS, 7 with BMI < 18.5 kg/m 2 , and 140 with missing information on baseline covariates were excluded, leaving 3729 patients in the final analysis. As compared with normal weight patients, those who were overweight (BMI: 25-29.9 kg/m 2 ) or obese (BMI ! 30 kg/m 2 ) tended to be younger, to not smoke cigarettes, and not have a history of prior stroke. As expected, as BMI increased, we observed increasing manifestations of metabolic syndrome, including higher blood pressure, WC, triglycerides, fasting glucose, HOMA-IR, and lower HDL concentration ( Table 1) .
Effect of adiposity on outcome risk
As compared to normal weight patients, overweight patients (BMI: 25-29.9 kg/m 2 ) did not have a significantly different risk for the composite outcome of stroke or MI (or for stroke alone and MI alone), or for all-cause mortality during follow-up ( Table 2,  Supplementary Table 1) . Patients with obesity (BMI ! 30 kg/m 2 ) had lower risks for stroke or MI (and stroke alone), and all-cause mortality compared to normal weight patients, but only the difference for all-cause mortality was significant after adjustment for baseline features (HR, 0.71; 95% confidence interval, 0.51-0.99; Table 2, Supplementary Table 1) .
When obesity was classified using WC, we observed lower risks for stroke or MI and mortality in patients with abdominal obesity compared to patients without abdominal obesity, but both results were not significant after adjustment. Risks were similar for groups defined using the waist-to-hip measure of obesity ( 
Effect of metabolic syndrome within adiposity strata
The presence of metabolic syndrome was associated with increased risk for stroke or MI and mortality in patients with normal BMI, but this effect was not observed in overweight or obese patients. Tests of interaction between BMI strata and HRs for metabolic syndrome and stroke or MI and mortality were significant (Figure 1, Supplementary Figure 1 ). In contrast, metabolic syndrome did not influence outcomes in any strata defined by WC or WHR (Supplementary Figure 2) .
Discussion
In the IRIS trial, metabolic syndrome was not associated with increased risk for mortality or the composite outcome of stroke or MI among patients with obesity (defined by any of three measures) and a recent ischemic stroke or TIA. However, metabolic syndrome was associated with a statistically significant and quantitatively large risk for these adverse outcomes in patients with a normal BMI.
Patients with normal weight and metabolic abnormalities, such as high body fat percentage or metabolic syndrome, have been termed ''normal-weight obese.'' [23] [24] [25] These patients have metabolic complications and inflammation related to factors other than weight, such as central adiposity, low birth weight, inactivity, ethnicity, and family history. 26, 27 Our finding that metabolic syndrome is a risk factor in normal BMI patients with cerebrovascular disease is consistent with prior population-based studies that have found normal weight obesity is associated with increased mortality 10,28-30 and cardiovascular disease. 31, 32 A biological explanation for this finding could be that certain normal weight individuals have a genetic predisposition to develop metabolic disease even with small increases in adiposity, leading to a higher cumulative risk of cardiovascular disease through their lifespan.
The lack of an association between metabolic syndrome and vascular outcomes or mortality in overweight and obese patients may be the result of IRIS selection criteria. All participants were insulin resistant, and, therefore, none of the overweight or obese patients had benign or ''healthy'' obesity. The majority of overweight and obese patients who did not meet criteria for metabolic syndrome had at least two features of the syndrome. In contrast, the majority of normal weight patients without metabolic syndrome had only one or no features. Thus, metabolic syndrome may better distinguish between patients with and without metabolic derangements in normal weight individuals compared to overweight or obese patients.
Counter to our findings in patients with a normal BMI, metabolic syndrome was not associated with significantly increased risk for stroke or MI or mortality in IRIS patients with normal WC or WHR.
Previous studies of patients with a recent ischemic stroke or TIA have demonstrated that metabolic syndrome is associated with risk for recurrent stroke. [14] [15] [16] [17] Our study differs from the prior research in several ways. First, we focused solely on non-diabetic patients, whereas, past studies included patients with diabetes, a condition also associated with increased risk. Second, International Journal of Stroke, 14(6) (10) 142 (9) 218 (13) Other/unknown 36 (6) 80 (5) 79 (5) Education, years, mean AE SD 13 AE 3 1 3 AE 3 1 3 AE 3
Clinical history
Prior stroke 98 (17) 173 (11) 190 (12) Atrial fibrillation 50 (9) 91 (6) 113 (7) Coronary artery disease a 67 (12) 189 (12) 195 (12) Peripheral vascular disease 28 (5) 88 (6) 102 (6) Current cigarette smoking 122 (21) 215 (14) 263 ( our study is the first to examine the effect of metabolic syndrome within weight strata and, therefore, was able to detect an interaction between weight and the effect of metabolic syndrome. Although we did observe a paradoxically lower risk for outcomes in patients with overall obesity by BMI or abdominal obesity by WC compared to non-obese patients, these findings were largely explained by differences in baseline risk. The exception was a finding of slightly lower mortality in patients with BMI ! 30 compared with normal BMI patients, and the substantial reduction in the HR for mortality before and after statistical adjustment suggests that residual confounding may be present.
The observation that central obesity (i.e., as measured by WC and WHR) did not confer a higher risk for outcomes in our data was surprising given the abundance of literature linking it with increased vascular risk and mortality in populations without vascular disease. [33] [34] [35] [36] One potential explanation for this finding is that WC and especially WHR may be prone to measurement error in this multi-site trial. It is also possible Our study had four notable limitations. First, our findings are based on data from a secondary prevention trial and may not be generalizable to patients from community-based samples. Second, because IRIS patients had insulin resistance without diabetes, the results may not apply to stroke patients without this metabolic profile. Third, the selection criteria for IRIS resulted in a more homogeneous population in which the spectrum of metabolic derangement may have been too narrow to detect differences between overweight and obese patients with and without metabolic syndrome, as all were insulin resistant. Fourth, we did not include weight at different time points, such as maximum lifetime or midlife weight, which may be more closely associated with vascular risk compared with weight at randomization. 9 Our findings draw new attention to the potential importance of metabolic derangements in normal weight patients after stroke or TIA. Because weight loss is not an appealing option for these patients, other interventions may be required, such as exercise and medications that ameliorate dysglycemia, insulin resistance, dyslipidemia, hypertension, and vascular inflammation. Our finding that metabolic syndrome was not associated with increased risk among patients who were overweight or obese does not mean that treatments directed at metabolic impairment, such as weight loss, would not be beneficial in this population. Ultimately, an accurate understanding of the influence of increased adiposity on prognosis in patients with symptomatic cerebrovascular disease will require randomized trials in which patients are assigned to weight loss or weight maintenance.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Inzucchi has served as a consultant to Janssen, vTv Therapeutics, and Alere; a clinical trial steering/executive committee member for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Daichii Sankyo, Eisai, and Sanofi/Lexicon; and a data-monitoring committee member for Intarcia. No other potential conflicts of interest relevant to this article were reported.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by National Institute of Neurological Disorders and Stroke grant (U01-NS-044876).
ORCID iD
Jennifer L Dearborn http://orcid.org/0000-0001-6733-1072
